Reviewing PharmaCyte Biotech (OTCMKTS:PMCBD) and Alpha Cognition (OTC:ACOGF)

PharmaCyte Biotech (OTCMKTS:PMCBD) and Alpha Cognition (OTC:ACOGF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Profitability

This table compares PharmaCyte Biotech and Alpha Cognition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PharmaCyte Biotech	N/A	-49.09%	-43.39%
Alpha Cognition	N/A	N/A	-522.43%

Analyst Recommendations

This is a summary of current recommendations and price targets for PharmaCyte Biotech and Alpha Cognition, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PharmaCyte Biotech	0	0	0	0	0.00
Alpha Cognition	0	0	1	0	3.00

Given Alpha Cognition’s stronger consensus rating and higher probable upside, analysts clearly believe Alpha Cognition is more favorable than PharmaCyte Biotech.

Volatility & Risk

PharmaCyte Biotech has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.8, indicating that its stock price is 180% more volatile than the S&P 500.

Institutional & Insider Ownership

0.0% of PharmaCyte Biotech shares are owned by institutional investors. 31.5% of Alpha Cognition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares PharmaCyte Biotech and Alpha Cognition”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A
Alpha Cognition	N/A	N/A	-$13.77 million	C($0.12)	N/A

Summary

Alpha Cognition beats PharmaCyte Biotech on 6 of the 9 factors compared between the two stocks.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

About Alpha Cognition

Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.